Analysts Offer Predictions for OCUL Q1 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – HC Wainwright issued their Q1 2027 earnings per share estimates for Ocular Therapeutix in a report released on Thursday, June 18th. HC Wainwright analyst Y. Chen anticipates that the biopharmaceutical company will post earnings per share of ($0.39) for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q3 2027 earnings at ($0.37) EPS.

Other equities analysts have also recently issued research reports about the company. William Blair restated an “outperform” rating on shares of Ocular Therapeutix in a report on Monday, March 2nd. Royal Bank Of Canada reiterated an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Robert W. Baird boosted their target price on shares of Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Tuesday, April 21st. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.89.

Ocular Therapeutix Stock Performance

Shares of NASDAQ:OCUL opened at $9.43 on Friday. The business’s 50-day simple moving average is $8.97 and its 200 day simple moving average is $9.92. The company has a market cap of $2.06 billion, a P/E ratio of -6.46 and a beta of 0.89. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. Ocular Therapeutix has a one year low of $6.23 and a one year high of $16.44.

Insider Buying and Selling

In related news, insider Pravin Dugel sold 21,156 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the transaction, the insider owned 2,597,170 shares of the company’s stock, valued at approximately $21,296,794. This represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 28,999 shares of company stock valued at $237,792 over the last ninety days. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Ocular Therapeutix

Institutional investors have recently made changes to their positions in the business. Citigroup Inc. increased its stake in Ocular Therapeutix by 574.4% during the third quarter. Citigroup Inc. now owns 673,348 shares of the biopharmaceutical company’s stock valued at $7,871,000 after purchasing an additional 573,504 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Ocular Therapeutix by 9.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,163,240 shares of the biopharmaceutical company’s stock worth $107,118,000 after buying an additional 771,065 shares during the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of Ocular Therapeutix in the 3rd quarter worth about $2,360,000. Avoro Capital Advisors LLC boosted its holdings in shares of Ocular Therapeutix by 38.5% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after buying an additional 2,850,000 shares during the period. Finally, Rhenman & Partners Asset Management AB bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $2,361,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.